Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.

ABSTRACT:

Background

Infliximab (IFX) use is limited by loss of response often due to the development of anti-IFX antibodies and low drug levels.

Methods

We performed a single center prospective observational cohort study of pediatric and young adult subjects with inflammatory bowel disease (IBD) on IFX with over 3 years of follow-up. Infliximab levels (IFXL) and antibodies to infliximab (ATI) were measured throughout the study. Subjects were followed until IFX was discontinued.

Results

We enrolled 219 subjects with IBD (184: Crohn's disease; 33: Ulcerative colitis; and 2 Indeterminant colitis; 84 female, median age 14.4 years, 37% on concomitant immunomodulator). Nine hundred and nineteen serum samples (mean 4.2 ± 2.1 per patient) were tested for IFXL and ATI. During the study

SUBMITTER: Zitomersky N 

PROVIDER: S-EPMC10883602 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature